<SEC-DOCUMENT>0001493152-25-016599.txt : 20251002
<SEC-HEADER>0001493152-25-016599.hdr.sgml : 20251002
<ACCEPTANCE-DATETIME>20251002070012
ACCESSION NUMBER:		0001493152-25-016599
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251002
FILED AS OF DATE:		20251002
DATE AS OF CHANGE:		20251002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CytoMed Therapeutics Ltd
		CENTRAL INDEX KEY:			0001873093
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41677
		FILM NUMBER:		251367008

	BUSINESS ADDRESS:	
		STREET 1:		#08-22 ONE COMMONWEALTH
		CITY:			1 COMMONWEALTH LANE
		STATE:			U0
		ZIP:			149544
		BUSINESS PHONE:		603824911

	MAIL ADDRESS:	
		STREET 1:		#08-22 ONE COMMONWEALTH
		CITY:			1 COMMONWEALTH LANE
		STATE:			U0
		ZIP:			149544

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CytoMed Therapeutics Pte. Ltd.
		DATE OF NAME CHANGE:	20210716
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of October 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number: 001-41677</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>CytoMed
Therapeutics Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1
Commonwealth Lane</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>#08-22</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Singapore
149544</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
of Principal Executive Office)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS FORM 6-K REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 2, 2025, CytoMed Therapeutics Limited (the &ldquo;Company&rdquo;) issued a press release announcing a publication based on collaborative
research with The University of Texas, MD Anderson Cancer Center, which demonstrates the potential of the Company&rsquo;s Allogeneic
&gamma;&delta; T Cells to treat Acute Myeloid Leukemia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Press Release dated October 2, 2025, titled: CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic &gamma;&delta; T Cells in Acute Myeloid Leukemia</A></FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CytoMed
    Therapeutics Limited</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    CHOO Chee Kong</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHOO
    Chee Kong</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    October 2, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chairman</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CytoMed
Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the
Potential of Allogeneic &gamma;&delta; T Cells in Acute Myeloid Leukemia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Singapore,
Singapore &ndash; (October 2, 2025) &ndash;</B> <U>CytoMed Therapeutics Limited</U> (NASDAQ: GDTC) (&ldquo;CytoMed&rdquo; or &ldquo;Company&rdquo;),
a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable
donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased
to announce the publication of a preclinical study, in a research article entitled &ldquo;<I>Donor-Derived V&gamma;9V&delta;2 T Cells
for Acute Myeloid Leukemia: A Promising &ldquo;off-the-shelf&rdquo; Immunotherapy Approach</I>&rdquo;. The study results from this collaborative
research with The University of Texas, MD Anderson Cancer Center (MDACC), are suggesting the promising potential of CytoMed&rsquo;s allogeneic
&gamma;&delta; T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This collaboration with MDACC is under a previously
announced research agreement in May 2023. The research article is now publicly and freely online at <U>Donor-Derived V&gamma;9V&delta;2
T Cells for Acute Myeloid Leukemia: A Promising &ldquo;Off-the-Shelf&rdquo; Immunotherapy Approach</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;These
findings provide the rationale for further clinical study of allogeneic donor-derived &gamma;&delta; T cells in treating AML as well
as other cancers. It will facilitate our endeavour to advance our next &gamma;&delta; T cell-based product into clinical trial after
our leading product CAR-&gamma;&delta; T cells (CTM-N2D), which is currently undergoing a Phase 1 clinical trial in Singapore.&rdquo;
said Dr. Zeng Jieming, M.D., Ph.D., Chief Scientific and Medical Officer of CytoMed and co-author of the paper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Peter Choo, Chairman of CytoMed commented, &ldquo;This research provides more evidence for applying allogeneic &gamma;&delta; T cells
to hematologic malignancies and we are planning to move into clinical trials in Southeast Asia and bring novel immunotherapy options
to patients with limited treatment alternatives.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
CytoMed Therapeutics Limited (CytoMed)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore&rsquo;s leading research and development
agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies,
namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for
the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T
therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating
the CAR-T principle into the treatment of solid tumours. For more information, please visit <U>www.cytomed.sg</U> and follow us on Twitter
(&ldquo;X&rdquo;) <U>@CytomedSG</U>, on <U>LinkedIn</U>, and <U>Facebook</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions
and other statements that are other than statements of historical facts. When the Company uses words such as &ldquo;may, &ldquo;will,
&ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo;
&ldquo;estimate&rdquo; or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results
to differ materially from the Company&rsquo;s expectations discussed in the forward-looking statements. These statements are subject
to uncertainties and risks including, but not limited to, the following: the Company&rsquo;s plans to develop and commercialize its product
candidates; the initiation, timing, progress and results of the Company&rsquo;s current and future pre-clinical studies and clinical
trials and the Company&rsquo;s R&amp;D programs; the Company&rsquo;s estimates regarding expenses, future revenue, capital requirements
and needs for additional financing; the Company&rsquo;s ability to successfully acquire or obtain licenses for additional product candidates
on reasonable terms; the Company&rsquo;s ability to establish and maintain collaborations and/or obtain additional funding and assumptions
underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional
factors are discussed in the Company&rsquo;s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes
no obligation to publicly revise these forward&ndash;looking statements to reflect events or circumstances that arise after the date
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact
:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CytoMed
Therapeutics Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enquiry@cytomed.sg</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention
: Evelyn Tan, Chief Corporate Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !( )8# 2(  A$! Q$!_\0
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M[R2QS*$@:Y_(K7=:_:3_ ."A'Q*USQ;XKUW3!H?@JQDUC7M>U[47\+_ _P"
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MS2EEL:]7'X>E1_KO),EEF?#.:<-Y1Q3P_P 2\&O)<^_LW 9=ELL-G^(AG?\
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MX*DMI;-?!<?A_1U\+/8R3&[FMD\."T_LB2TENF>\E1;0PRW3M<,IG8L?I_\
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MD  Z=^3]>F?THHKPTDFVDDWO96_X'W)>=SV?Z_KJ_FV+1113 **** "BBB@
.HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
